Sunday, October 4, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· April 13, 2026

Dollar firms on safe-haven demand amid escalating U.S.-Iran tensions: Currency Recap

View original at seekingalpha.com
Dollar firms on safe-haven demand amid escalating U.S.-Iran tensions: Currency Recap ardasavasciogullari The U.S. dollar edged up on Monday, as investors turned cautious following renewed geopolitical tensions and a shift back toward safe-haven demand after the collapse of U.S.-Iran peace talks…
Opening lines of the source · Seeking Alpha · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • U.S. recession odds fade as economic data keep beating expectations

    60% confidence
  • Commodities to lead 'anything but bonds' trade through 2020s

    60% confidence
  • The dollar's rebound was supported by shifting expectations around global interest rate outlook, as rising energy prices and persistent inflation pressures reduced likelihood of near-term policy easing by major central banks

    60% confidence
  • The Japanese yen weakened even as geopolitical tensions escalated, suggesting limited safe-haven demand amid broader dollar strength

    60% confidence
  • Risk aversion intensified toward the latter part of the week as diplomatic efforts faltered and tensions escalated, including renewed threats to key energy shipping routes such as the Strait of Hormuz

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com